Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 2031-2035

  Madsen Duggan, Christina B ^a   Debenham, John S ^a   Walsh, Thomas F ^a   Toupence, Richard B ^a   Huang, Song X ^a   Wang, Junying ^a   Tong, Xinchun ^a   Lao, Julie ^a   Fong, Tung M ^a   Schaeffer, Marie Therese ^a   Xiao, Jing Chen ^a   Huang, Cathy R R C ^a   Shen, Chun Pyn ^a   Stribling, D Sloan ^a   Shearman, Lauren P ^a   Strack, Alison M ^a   MacIntyre, D Euan ^a   Van der Ploeg, Lex H T ^a   Goulet, Mark T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cannabinoid; CB1; Inverse agonist; Obesity; Pyridine

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; PYRIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SCREENING; FOOD INTAKE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BEHAVIOR, ANIMAL; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; FEEDING BEHAVIOR; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; TOLUENE;

EID: 33847685325     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.005     Document Type: Article

References (13)

1. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Mol. Pharmacol. 34 (1988) 605
2. For extensive reviews in this area, see the following:. Muccioli G.G., and Lambert D.M. Curr. Med. Chem. 12 (2005) 1361
3. Hertzog D.L. Expert Opin. Ther. Patents 14 (2004) 1435
4. Smith R.A., and Fathi Z. Idrugs 8 (2005) 53
5. Lange J.H.M., and Kruse C.G. Curr. Opin. Drug Discov. Devel. 7 (2004) 498
6. Lange J.H.M., and Kruse C.G. Drug Discovery Today 10 (2005) 693
7. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reinecke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C.E., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. J. Clin. Invest. 112 (2003) 423
8. Després J.-P., Golay A., and Sjöström L. N. Eng. J. Med. 353 (2005) 2121
9. ® (rimonabant) approved in the European Union, June 21, 2006, www.sanofi-aventis.com.
10. Meurer L.C., Finke P.E., Mills S.G., Walsh T.F., Toupence R.B., Debenham J.S., Goulet M.T., Wang J., Tong X., Fong T.M., Lao J., Schaeffer M.-T., Chen J., Shen C.-P., Stribling D.S., Shearman L.P., Strack A.M., and Van der Ploeg L.H.T. Bioorg. Med. Chem. Lett. 15 (2005) 681 1755
11. Debenham J.S., Madsen-Duggan C.B., Walsh T.F., Wang J., Tong X., Doss G.A., Lao J., Fong T.M., Schaeffer M.-T., Xiao J.C., Huang C.R.-R.C., Shen C.-P., Feng Y., Marsh D.J., Stribling D.S., Shearman L.P., Strack A.M., MacIntyre D.E., Van der Ploeg L.H.T., and Goulet M.T. Bioorg. Med. Chem. Lett. 16 (2006) 681
12. For comparison the calculated log D for 1a, 3f, and 15c is 8.35, 8.08, and 6.19, respectively (Advanced Chemistry Development log D software version 8.07).
13. The reported binding results were an average of 2-8 independent determinations (each done in replicate), which were normally within 50% of the average value. For both binding and functional assay conditions, see:. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., and Mitchell R.L. Mol. Pharmacol. 48 (1995) 443